|
週次 |
日期 |
單元主題 |
|
第2週 |
9/23 |
Inhibitors – cellular aspects and novel approaches for tolerance
Rituximab as first-line treatment for the management of adult patients with non-severe hemophilia A and inhibitors
|
|
第4週 |
10/07 |
Epidemiological aspects of inhibitor development redefine the clinical importance of inhibitors
Inhibitors – genetic and environmental factors
Antiplatelet therapy: new pharmacological agents and changing paradigms
|
|
第6週 |
10/21 |
Haemophilia care – beyond the treatment guidelines
Current status of haemophilia gene therapy
|
|
第8週 |
11/04 |
Rare bleeding disorders – bleeding assessment tools, laboratory aspects and phenotype and therapy of FXI deficiency
Mechanisms underlying platelet function defect in a pedigree with familial platelet disorder with a predisposition to acute myelogenous leukemia: potential role for candidate RUNX1 targets
Energy and motion: AMP-activated protein kinase α1 and its role in platelet activation
The Ca2+/calmodulin-dependent kinase kinase β-AMP-activated protein kinase-α1 pathway regulates phosphorylation of cytoskeletal targets in thrombin-stimulated human platelets
|
|
第10週 |
11/18 |
Genomics of bleeding disorders
Genetic testing in bleeding disorders
|
|
第12週 |
12/02 |
Primary haemostasis: newer insights
Novel products for haemostasis – current status
With blood in the joint – what happens next? Could activation of a pro-inflammatory signalling axis leading to iRhom2/TNFα-convertase-dependent release of TNFα contribute to haemophilic arthropathy?
Oral gene therapy for hemophilia B using chitosan-formulated FIX mutants
|
|
第14週 |
12/16 |
Monitoring of modified factor VIII and IX products
Amplification of human platelet activation by surface pannexin-1 channels
Laboratory testing for factor inhibitors
Changing paradigm of prophylaxis with longer acting factor concentrates
|
|
第16週 |
12/30 |
von Willebrand disease and platelet disorders
Protein kinase C and P2Y12 take center stage in thrombin-mediated activation of mammalian target of rapamycin complex 1 in human platelets
Novel products for haemostasis
Prophylaxis in real life scenarios
|